Top Injectable Manufacturer in Namibia – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 5 days ago
- 13 min read
Last Updated: September 1, 2026
TL;DR: Namibia does not fit either pattern this series has been finding. It is not a market with a closed reference-country list that excludes India, and it is not a market with no list at all. The gazetted regulation creates the recognition hook in deliberately open language — registration granted by “other medicines regulatory authorities recognised by the Council” — and names nobody. The Council's actual list of recognised authorities lives in an online library we could not open, so we will tell you plainly that we do not know whether India appears on it, rather than guess in either direction. What we can tell you from the gazette itself is more useful than the list would be: regulation 45 couples the State tender to the registration file, so a medicine tendered internationally to the State can be supplied on an expedited basis once the manufacturing site has passed a WHO-guideline GMP inspection and the registration application is in. Namibia is a founding and currently active member of the ZaZiBoNa collaborative procedure, which is genuinely open to an Indian applicant but is work-sharing rather than register-once. And because out-of-pocket spending is only 7.49% of current health expenditure, the buyer here is the State, which makes the procurement regulations — not the dossier — the place where a foreign supplier actually wins or loses.
Key Takeaways
The recognition clause names nobody, and we could not read the list. Regulation 45(2)(c) of the 2008 Regulations under the Medicines and Related Substances Control Act 13 of 2003 recognises registration granted by “other medicines regulatory authorities recognised by the Council”, and regulation 45(4) permits an abbreviated review on the same basis. No country is enumerated in the gazette. The Namibia Medicines Regulatory Council's own site says the list of stringent regulatory authorities it aligns with sits in its E-library — which returned an empty page for us, as did the Council's home page, its guidelines page and the official copy of its CTD guideline. We therefore do not know whether India is on that list, and we say so rather than inventing a negative. It is the first question to put to the Registrar.
The tender route and the registration file are deliberately coupled, and that is the most useful thing in the gazette. Regulation 45(1)(c) brings “any medicine tendered internationally to the State for supply to state hospitals and state health facilities” into the expedited process. Regulation 45(2) then permits supply where the manufacturing facilities have been approved by a GMP inspection conducted according to World Health Organization guidelines and a registration application has been submitted before supply, with a three-month review clock under 45(5). WHO GMP — not EU or PIC/S GMP — is the benchmark the regulation actually names, which is the right benchmark for an Indian WHO-GMP site.
A local representative is mandatory and carries real answerability. Regulation 3(1)(b) allows the foreign manufacturer itself to be the applicant, so a registration need not be surrendered to a distributor. But regulation 3(5) requires an applicant not resident in Namibia to appoint a local representative, and regulation 3(6) provides that the representative “will be answerable to the Council in respect of the quality, safety and efficacy of the medicine”. Regulation 3(4) separately requires a named pharmacist or technical representative responsible for liaising with the Council. Both appointments are structural, not administrative.
The commercial gate is procurement, and it is tilted. With out-of-pocket spending at 7.49% of current health expenditure in 2023, Namibia is not a cash-pay market. Under the Public Procurement Regulations a bid security is mandatory above N$500,000, and where that security is a foreign bank guarantee the bidder must supply a counter-guarantee from a Namibian commercial bank. Public entities must encourage joint ventures and must give more weight to entities demonstrating that more than 60 per cent of key employees are Namibian, while preference beneficiaries may be exempted from bid security altogether. A foreign bidder is not excluded, but it is structurally disadvantaged unless it partners locally.
Introduction: Why Namibia Demands a Premium Injectable Manufacturer in Namibia
For several markets in this series the opening research question has produced one of two answers. Either the country publishes a closed list of regulators whose approvals it will lean on and India is not among them, or — as Qatar turned out — there is no list at all and the constraints sit somewhere else entirely. Namibia produced a third answer, and it is the least comfortable of the three to write about honestly. The recognition hook exists and is gazetted, but it names nobody. Regulation 45 of the 2008 Regulations made under the Medicines and Related Substances Control Act 13 of 2003 permits supply where “a registration has been granted by other medicines regulatory authorities recognised by the Council”, and permits an abbreviated medicine review process where another authority has already registered the product for the purpose applied for. Who those authorities are is not in the gazette. It is an administrative matter for the Namibia Medicines Regulatory Council.
We tried to read that list and failed. The Council's registration page states that the list of stringent regulatory authorities and organisations it aligns with can be found in its E-library; the E-library returned a completely empty page, as did the Council's home page, its medicine registration overview, its guidelines index and the official copy of its own CTD submission guideline, which we ultimately had to read from a mirror. We are telling you this because the alternative is worse. A confident sentence saying India is not recognised by Namibia would be an invented negative, and a confident sentence saying it is would be wishful. What we will do instead is set out what the gazette itself says, which is enough to plan around, and name the E-library list as the first question a serious buyer should put to the Registrar in writing before spending money on a file.
What Sets a World-Class Injectable Manufacturer in Namibia Apart
Start with the dossier, because it is straightforward and it is one of the few things in this market that is. Namibia works in the Common Technical Document format, not the ASEAN variant, under a guideline for submission of applications for registration of pharmaceuticals for human use in CTD format that is built on ICH structure together with the World Health Organization's multisource generics guidance. Module 1 is Namibia-specific, and we will be honest that we could not open the Module 1 specification itself — the mirror we found returned a bot-block — so we cannot tell you its exact contents. Submissions go in electronically on disc with text-selectable PDFs for all five modules plus editable files for the quality overall summary and the templates, a screening fee is paid first and the application fee follows once screening is passed, and the applicant has ninety days to answer queries. Bioequivalence data is mandatory for generics, with biowaivers available for immediate-release solid orals in BCS Class I and III and narrow-therapeutic-index products excluded. The Council sits four times a year.
The documentary requirements for a foreign manufacturing site are precise and, for a WHO-GMP holder, entirely reachable. Regulation 5(e) requires a certified copy of the manufacturing licence together with a current good manufacturing practice certificate from the medicines regulatory authority of the country of origin. Regulation 5(f) requires a site master file. Regulation 3(2) requires a foreign applicant to prove registration as a pharmaceutical manufacturer with its home regulator and to hold a current GMP certificate from that regulator, and regulation 3(3) gives the Council express power to make such investigations as it considers necessary to verify any of it. Regulation 43(2) goes further and provides that the Council “must ensure through regular inspections” that all medicines registered in Namibia are manufactured according to WHO current GMP guidelines. Note carefully what that means: a home-regulator GMP certificate is a required document, not a substitute for inspection. Anyone who tells you a WHO-GMP certificate closes the GMP question in Namibia has read regulation 5(e) and stopped there.
Quality Systems Behind Every Injectable Supplied to Namibia
There are two documentary points where we will not pretend to certainty. The first is the certificate of a pharmaceutical product. Regulation 5(e) speaks of a manufacturing licence and a GMP certificate; we found no explicit CPP requirement anywhere in the 2008 Regulations. A CPP requirement may well sit in the Module 1 specification or the application form annexure we could not open, so we are not saying Namibia requires one and we are not saying it does not. Prepare one, because it is cheap insurance and every neighbouring market wants it, but do not let anyone tell you the regulation demands it on the strength of a summary. The second is legalisation. The regulations say “certified copy” and specify no notarisation, apostille or embassy attestation chain, and we did not verify Namibia's status under the Hague Apostille Convention. That is a question for the Registrar, not for an article.
A third point is a genuine conflict between the gazette and current practice, and it is the kind of small thing that wastes a shipment. Regulation 5(a) of the 2008 Regulations requires three samples of the medicine in the smallest of each of the package forms. The Council's own website and its published FAQ both say one sample per strength in the smallest pack size. Those are not the same requirement, and the gazetted regulation has not obviously been amended to match the practice. Confirm in writing before you ship, and note the one piece of good news attached to it: the Council states that no import licence is needed for registration samples. On timelines, we will give you the Council's own words rather than a consultant's estimate, because they are more honest than anything we could construct: “There are currently no specific timelines for the registration of medicines, owing to the current backlog of applications.” The only statutory clock we found anywhere is the three months in regulation 45(5), and it applies to the tender route.
Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry.
Why Farbe Firma is the Trusted Injectable Manufacturer in Namibia for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries. We build dossiers in CTD and ACTD format, maintain the analytical infrastructure a regulator expects to see behind a file — HPLC, GC, LAL endotoxin testing, Karl Fischer moisture determination and ICH Q1A and Q1B stability programmes — and we are used to markets where the manufacturer is the applicant of record rather than a name on someone else's certificate. Namibia's regulation 3(1)(b) is precisely such a route, and we would encourage any buyer to think carefully before giving that position away, because regulation 3(6) makes the local representative answerable to the Council for quality, safety and efficacy, and you want that person to be someone you chose rather than someone who chose you.
The regional dimension deserves accuracy rather than enthusiasm. Namibia is a founding member of the ZaZiBoNa collaborative medicines registration procedure — it is the “Na” — and it is currently classified as active, meaning it has the capacity to conduct both assessments and GMP inspections. Eligibility is dossier-based, not domicile-based, so there is no visible barrier to an Indian applicant. What it is not is a single registration valid across Southern Africa. Entry requires an identical dossier filed in a minimum of two participating countries with the national fees paid in each, and the Council's own description of the outcome is that individual countries “can rely on this decision at country level to subsequently register or not register a product in the country based on local regulatory requirements”. Rely, not bind. Treat ZaZiBoNa as a way to make one assessment do the work of several, which is real value, and not as a passport, which it is not. It is also worth knowing that the World Health Organization conducted an assisted self-benchmarking of the Council in Windhoek in October 2025 and described it as advancing toward maturity level 3 — so not yet there, and not a WHO Listed Authority, but moving, with a new Medicines and Related Substances Control Bill drafted to replace the 2003 Act and an ISO/IEC 17025 accredited national quality control laboratory now in place.
Which brings us to where the money actually is, and it is not the dossier. Namibia spent about 9.48% of GDP on health in 2023 at roughly USD 397 per person, against a population of about 3.09 million and gross national income per capita of about USD 4,340. But out-of-pocket spending was only 7.49% of current health expenditure. That single number tells you the shape of the market: this is a public-budget and medical-aid market, not a pharmacy-counter one, and the disease burden points the same way, with adult HIV prevalence around 9.0% and tuberculosis incidence around 422 per 100,000 in 2024. The buyer is the State, and the State buys under the Public Procurement Act and its regulations, where the asymmetries are explicit. A bid security is mandatory above N$500,000 and a foreign bank guarantee must be backed by a Namibian commercial bank counter-guarantee. Public entities must encourage joint ventures with Namibian bidders and must give more weight to entities showing more than sixty per cent Namibian key employees. Preference beneficiaries can be exempted from bid security entirely. We could not read the annexures carrying the threshold values and the margin of preference, because they are embedded images, and we are not going to quote numbers we did not see. But the direction is unambiguous, and the strategic conclusion follows from it: in Namibia the registration file is the easy half. Build the local partnership first, because regulation 45 will let the tender pull the registration along behind it, and the procurement rules will decide the outcome long before the Council does.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is India on Namibia's list of recognised regulatory authorities?
We do not know, and we are not going to pretend otherwise. The gazetted regulation — regulation 45(2)(c) and 45(4) of the 2008 Regulations under the Medicines and Related Substances Control Act 13 of 2003 — refers only to “other medicines regulatory authorities recognised by the Council” and enumerates nobody. The Namibia Medicines Regulatory Council's registration page states that the list of stringent regulatory authorities and organisations it aligns with is held in its E-library. That E-library returned an empty page for us on every attempt, as did several other pages on the same portal, which appears to render its content in a way our tools could not retrieve. So the honest position is that the list exists, we did not see it, and India's status on it is unknown in both directions. Put it to the Registrar in writing before you budget a file around it. Note separately that the World Health Organization collaborative registration procedure for prequalified products is explicitly encouraged by the Council, and that route does not depend on the list at all.
Will our WHO-GMP certificate from CDSCO be accepted, or will the Council inspect us?
Both propositions are true at once and the distinction matters. Regulation 5(e) requires a certified copy of the manufacturing licence together with a current GMP certificate from the medicines regulatory authority of the country of origin, and regulation 3(2) requires a foreign applicant to prove home-regulator registration and hold a current GMP certificate. So the document is required and a CDSCO-issued WHO-GMP certificate is the document the regulation contemplates. But regulation 3(3) gives the Council express power to make whatever investigations it considers necessary, and regulation 43(2) obliges it to ensure through regular inspections that every medicine registered in Namibia is manufactured to WHO current GMP guidelines. The certificate is therefore a required input, not a waiver of inspection. Worth knowing too that the benchmark named in the regulation is WHO GMP rather than EU or PIC/S GMP, which is favourable positioning for an Indian site — and that neither Namibia nor India is a PIC/S participating authority or applicant, so no PIC/S-based shortcut exists in either direction.
Does ZaZiBoNa mean we can register once and sell across Southern Africa?
No, and this is the most common misunderstanding about the procedure. Namibia is a founding and currently active member, and active status means it can carry out both assessments and GMP inspections. Eligibility is based on the dossier, not the applicant's nationality, so an Indian manufacturer can participate. But the procedure is work-sharing, not mutual recognition. To enter it you must submit an identical dossier to a minimum of two participating countries and pay the national registration fees in each. When the joint assessment concludes, the Council's own description is that individual countries can rely on the decision to subsequently register or not register the product based on local regulatory requirements. National registration remains a separate act in every country. The genuine value is that one assessment can support several national decisions, which compresses cost and calendar across a regional launch. The value it does not have is a single Southern African marketing authorisation, because no such thing exists.
How long does registration take and what will it cost?
On timing we will quote the Council rather than estimate: its published FAQ states that there are currently no specific timelines for the registration of medicines, owing to the current backlog of applications. Any figure you are given in months for the ordinary route is somebody's guess. The single statutory clock we located is the three-month review period in regulation 45(5), which attaches to applications made under the tender-linked expedited route, and that is a strong argument for entering through a State tender rather than through an ordinary filing. On cost we have to be equally direct: fees are set by a statutory schedule published in Government Gazette 7608 in 2021, which is held in the same E-library we could not open, so we have no verified registration, screening, fast-track or collaborative-procedure fee to give you. The one figure published in the Council's FAQ is N$1,500 for variations that require a new registration certificate, with certain minor variation types exempt. Budget from the gazette once you have it, not from an article.
Is Namibia a tender market, and what does that mean for a foreign supplier?
Overwhelmingly, yes. Out-of-pocket spending was 7.49% of current health expenditure in 2023, which means almost nothing is bought at a pharmacy counter with a patient's own money; the State and the medical aid schemes are the demand. Public buying runs under the Public Procurement Act 15 of 2015 and its regulations, with the Central Procurement Board conducting bidding above the public-entity threshold and the Ministry of Health's Central Medical Stores as the warehousing and distribution arm. Three features of the regulations shape a foreign bid. A bid security is mandatory where the contract value exceeds N$500,000, and if it takes the form of a foreign bank guarantee the bidder must also provide a counter-guarantee from a Namibian commercial bank. Public entities must encourage joint ventures between foreign entities and Namibian bidders and must give more weight to entities demonstrating that more than sixty per cent of key employees are Namibian. And bidders qualifying for national preference may be exempted from bid security altogether. None of that bars a foreign supplier, but all of it argues for a local partner rather than a direct bid. We were unable to read the annexures containing the threshold values, the standard security rates and the margin of preference, because they are embedded images in the published regulations, so confirm those figures from the gazette before you model a bid.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments